Edison Investment Research - Brainstorm Cell Therapeutics (BCLI) Update: Termination of coverage

Report

Edison Investment Research

Update: Termination of coverage

Edison Investment Research is terminating coverage on Brainstorm Cell Therapeutics (BCLI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

22/02/2016 1 EN

Underlying

Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics is a biotechnology company engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases including: Amyotrophic Lateral Sclerosis; Progressive Multiple Sclerosis; and Parkinson's disease. NurOwn? technology is based on manufacturing protocol, which induces the differentiation of purified and expanded bone marrow-derived mesenchymal stem cells and consistently generates cells that release multiple neurotrophic factors to modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.

See profile

US10501E2019 NASDAQ Stock Market United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

ACF Equity Research

BrainStorm Cell Therapeutics Inc Core Investment Case 13032024

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) is a biotechnology company focused on developing autologous mesenchymal stem cell (MSC) therapies for the treatment of neurodegenerative diseases – BCLI’s primary target is the fatal amyotrophic lateral sclerosis (ALS/MND/Lou Gehrig’s). BCLI’s’s proprietary technology platform, NurOwnTM, stimulates Mesenchymal Stem Cells to emit neurotrophic factors (MSC-NTF), which promote the survival of neurons across multiple disease states.

March 13, 2024 March 13, 2024 1 EN

GlobeNewsWire

Catalent und BrainStorm Cell Therapeutics geben Partnerschaft zur Herstellung von NurOwn®, einer auf mesenchymalen Stammzellen beruhenden Therapie, bekannt

Catalent und BrainStorm Cell Therapeutics geben Partnerschaft zur Herstellung von NurOwn®, einer auf mesenchymalen Stammzellen beruhenden Therapie, bekannt SOMERSET, N.J. und NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), der weltweit führende Anbieter von modernen Verabreichungstechnologien, Entwicklungs- und Fertigungslösungen für Arzneimittel, Biologika, Zell- und Gentherapien sowie Produkte im Bereich Verbrauchergesundheit, und BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), ein führender Entwickler von zellulären Therapien für die Behandlung neurodegenerativer E...

October 23, 2020 October 23, 2020 1 EN

GlobeNewsWire

Catalent et BrainStorm Cell Therapeutics annoncent un partenariat pour la conception de la plateforme de thérapie par cellules souches mésenchymateuses NurOwn®

Catalent et BrainStorm Cell Therapeutics annoncent un partenariat pour la conception de la plateforme de thérapie par cellules souches mésenchymateuses NurOwn® SOMERSET, N.J.et NEW YORK, 23 oct. 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE : CTLT), le plus grand fournisseur mondial de solutions de fabrication, de développement et de technologies d'administration de médicaments, de produits biologiques, de thérapies cellulaires et génétiques et de produits de santé grand public, et BrainStorm Cell Therapeutics Inc. (NASDAQ : BCLI), un développeur de premier plan de thérapies cellulaires pour le...

October 23, 2020 October 23, 2020 1 EN

Biodexa Pharmaceuticals - In a period of transition

FY23 was a transitional year for Biodexa, following the restructuring announced in March 2023 into a therapeutic company from a drug delivery specialist, and the implementation of cost-saving initiatives in light of the macroeconomic environment. The pipeline expansion primarily de-risks the business, partially fulfilled with the acquisition of lyn kinase activator tolimidone, for type 1 diabetes (T1D), in late 2023. Management estimates gross cash of £5.97m at end-FY23 to provide a runway into Q424, past the planned Phase IIa trial initiation for tolimidone. The next catalyst will likely be t...

1h / 6m 1h / 6m 1 EN

Toby Thorrington

Toby Thorrington

Norcros - Sale of Johnson Tiles UK agreed

Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well-covered dividend. We retain our estimates and value the shares at 246p, implying c 30% upside.

18h / 45m 18h / 45m 1 EN

Pedro Fonseca

Pedro Fonseca

Henderson Far East Income - Repositioning to raise total returns

Henderson Far East Income (HFEL) has consistently delivered on its objective to provide a rising dividend. However, like many investors, HFEL’s managers overestimated the potential for a post-pandemic rebound in China. The trust’s resultant overweight to Chinese consumer and other cyclicals led to a fall in portfolio revenues and underperformance in the financial year ended 31 August 2023 (FY23). With a view to improving future returns, HFEL’s board has since indicated an increased willingness to use reserves when necessary to support dividend payments, which it did in FY23. This reduces the r...

21h / 35m 21h / 35m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN